Zhang T, Stanley S L
Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.
Vaccine. 1997 Aug-Sep;15(12-13):1319-22. doi: 10.1016/s0264-410x(97)00042-x.
Infection by the intestinal protozoan parasite Entamoeba histolytica remains a significant threat to health in much of the world. Here we describe the successful expression of the serine rich Entamoeba histolytica protein (SREHP), a protective antigen of ameba, in an attenuated vaccine strain Salmonella typhi TY2 chi 4297 (delta cya delta crp delta asd). The attenuation of S. typhi TY2 chi 4297 was not altered by expression of the SREHP-maltose binding protein (MBP) fusion protein and mice parenterally vaccinated with S. typhi TY2 chi 4297 expressing SREHP-MBP developed serum anti-amebic and anti-LPS antibodies. S. typhi TY2 chi 4297 expressing SREHP-MBP represents a prototype combination vaccine designed to prevent both amebiasis and typhoid fever.
在世界许多地区，肠道原生动物寄生虫溶组织内阿米巴的感染仍然对健康构成重大威胁。在此，我们描述了富含丝氨酸的溶组织内阿米巴蛋白（SREHP），一种阿米巴的保护性抗原，在减毒疫苗菌株伤寒沙门氏菌TY2 chi 4297（Δcya Δcrp Δasd）中的成功表达。表达SREHP-麦芽糖结合蛋白（MBP）融合蛋白并未改变伤寒沙门氏菌TY2 chi 4297的减毒特性，经皮下接种表达SREHP-MBP的伤寒沙门氏菌TY2 chi 4297的小鼠产生了血清抗阿米巴和抗LPS抗体。表达SREHP-MBP的伤寒沙门氏菌TY2 chi 4297代表了一种旨在预防阿米巴病和伤寒热的原型联合疫苗。
